INTERVIEWS

Jay Wish MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for outpatient dialysis at Indiana University Health, discusses the challenges of maintaining healthy phosphorus levels in patients. Hyperphosphatemia, or an electrolyte disorder in which there is an elevated level of phosphate in the blood, can cause serious cardiac conditions. In this episode, he discusses the current challenges in care, his recent peer-reviewed data on phosphate management and the latest research on potential new solutions on the horizon for CKD patients in need. This discussion comes just ahead of ASN’s Kidney Week where there will be new data on the impact of hyperphosphatemia on CKD patients and potential new treatments.

Dr. Daniel Croley, DMD, Chief Dental Officer at Delta Dental of California and Affiliates discusses Delta Dental’s Senior Oral Health Report: Older Americans’ Oral Care Regrets, Barriers and Impact which revealed that Americans aged 50 and older wish they had gone to the dentist more when younger and other key findings. He also shares tips on how older Americans can get their smile back on track.

Dr. Wendy Pang, Senior Vice President, Research and Translational Medicine at Jasper Therapeutics, a company transforming the field of hematopoietic stem cell (HSC) therapies discusses how cell and gene therapies are important and potentially curative therapies for people with life-threatening leukemias/lymphomas, other hematologic cancers and inherited genetic diseases. Current conditioning regimens, which are used to help make space for the transplanted cells, unfortunately, have significant toxicities that can limit their use. The company is using new insights into HSC biology to enable new approaches to improve the safety and efficacy of cell transplant-based therapies, and to develop standalone therapeutics. The company’s lead candidate, JSP191, is being evaluated as both a conditioning agent and a standalone therapy.

Dr. ​Gregory ​Randolph​, MD, FACS, FACE, Director, Thyroid and Parathyroid Endocrine Surgical Division at Mass Eye and Ear talks​ about his study on Advanced Thyroid Cancer – State of the Art Management that was presented at the 2022 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) annual meeting.

Sean Bohen, M.D., Ph.D., is President and CEO of Olema Oncology, a company committed to improving outcomes for women living with cancer. Dr. Bohen discusses Olema’s lead investigational asset, OP-1250, now in Phase 2 clinical development for women with recurrent, locally advanced, or metastatic ER+/HER2- breast cancer. The initial data from Olema’s Phase 1 studies provide proof-of-concept supporting OP-1250’s potential as a once-daily oral therapy with attractive pharmacokinetics, favorable tolerability, and anti-tumor activity both as a monotherapy or in combination with current treatments.

Dr. Flavia C. L. Hoyte, Allergist and Immunologist, National Jewish Health in Denver, CO, and Associate Professor, Medicine-Allergy/Clinical Immunology at the University of Colorado Hospital, Aurora, CO discusses the first ever CONNECT1 clinical study to evaluate the ProAir ® Digihaler ® (albuterol sulfate), a smart inhaler system compared to standard of care. It has built-in sensors that automatically record the patient’s inhalations, to help them and their doctor personalize their treatment plan. The study showed that adults and children aged 13 and older with uncontrolled asthma using the ProAir Digihaler System experienced improvements in controlling their asthma compared with those using standard-of-care albuterol inhalers.

Dr. Lora Shahine, MD, FACOG, a reproductive endocrinologist at Pacific Northwest Fertility and Associate Clinical Professor at the University of Washington discusses how remote work has made navigating the logistics of fertility more convenient for people on their paths to parenthood, but also more isolating. The advantages of improved privacy, reduced work stress, and the ease of scheduled appointments are offset by the challenges of the need for community, support, and resources. Those looking to find support and a social community can visit www.fertilityoutloud.com.

For 150 years, dentists have used amalgam fillings to fill and repair cavity-stricken teeth, but a newly released study indicates those fillings – which contain 50% mercury – may slowly be poisoning the people they were designed to help. Dr. Mark Geier and Mr. David Geier, authors of a new study “Dental Amalgam Fillings and Mercury Vapor Safety Limits in American Adults” that evaluated mercury vapor safety limits, discuss the findings and offer solutions for those concerned about the safety of their dental fillings.

Dr. John Laird, an interventional cardiologist and Vice President and Chief Medical Officer of Peripheral Vascular Health at Medtronic discusses peripheral artery disease (PAD), risk factors, signs and symptom management, and treatment options.

Dr. Firas Zahr, MD, interventional cardiologist and co-director of the Complex Heart Valve Program at Oregon Health & Science University (OHSU) and Director of Interventional Cardiology at OHSU discusses findings from the Intrepid™ Early Feasibility Study Intermediate-Term Outcomes which were presented as part of the Mitral Innovation Session, at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Results demonstrated successful device implantation and valve performance and include higher rates of successful device implantation (96.7%) and near complete elimination of mitral regurgitation (MR) in all patients (91%).  Visit the Apollo Intrepid Transcatheter Mitral Valve Regurgitation Clinical Trial at Medtronic.com under the Healthcare Professionals Tab.